OTLK Outlook Therapeutics, Inc.
$0.51▼ -0.41%
Healthcare
Other
Volume 204.2K
Avg Volume (10D) 4.03M
Key Metrics & Fundamentals
Market Cap
$124.45M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.16 - 2.54
% vs 50 MA
-16.39%
% vs 200 MA
-22.68%
RSI-14
39.8
MACD Histogram
+0.0100
Beta (1Y vs SPY)
1.03
Free Cash Flow
-$21.01M
Gross Rev
$8,700
Gross Profit
-$8,265
EBITDA
-$2.43M
COGS
$16,965
Operating Exp
$10.80M
Operating Income
-$10.81M
EBIT
-$10.81M
Pretax Income
-$20.32M
Net Income
-$20.32M
EPS (Diluted)
-0.15
Price & Volume History
Loading chart…
Recent News
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
MT Newswires · Oct 9, 2026 9:12 AM ET
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
GlobeNewswire · Oct 9, 2026 8:30 AM ET
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion
GlobeNewswire · Oct 6, 2026 9:20 AM ET
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
GlobeNewswire · Oct 1, 2026 9:01 AM ET
Inside the Eye-Drug Breakthrough That Sent Kodiak Sciences Up 183%
Barrons.com · Sep 28, 2026 3:16 PM ET
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
GlobeNewswire · Sep 11, 2026 7:00 AM ET
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
GlobeNewswire · Sep 10, 2026 9:10 AM ET
Outlook Therapeutics Appoints Kevin Lundquist as CFO
MT Newswires · Aug 27, 2026 4:39 PM ET
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
GlobeNewswire · Aug 27, 2026 4:05 PM ET
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
GlobeNewswire · Aug 27, 2026 9:01 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See OTLK's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.